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Aim: To clarify prognostic factors of metatstatic urothelial carcinoma treated by systemic chemotherapy in real-world clinical practice in
the Japanese population.
Materials and methods: A total of 228 patients with metastatic urothelial carcinoma undergoing systemic chemotherapy between 2000 and 2013
were included in the present multi-institutional study. The gemcitabine plus cisplatin regimen was administered as ﬁrst-line chemotherapy to 131
patients, whereas methotrexate, vinblastine, doxorubicin, and cisplatin or its modiﬁed regimen was given to 71 patients. Of the 228 patients, 119
received at least 2 different regimens and 22 underwent resection of metastases (metastasectomy). Multivariate survival analysis was performed using
the Cox proportional hazards model. The characteristics included were age, sex, Eastern Cooperative Oncology Group performance status (PS), primary
site, pathology of primary site, hemoglobin levels, lactate dehydrogenase levels, C-reactive protein levels, corrected calcium levels, estimated glomerular
ﬁltration rate levels, history of prior chemotherapy, metastatic sites, resection of primary site, number of metastatic organs, and metastasectomy.
Results: The median overall survival (OS) time was 17 months. On multivariate analysis, female sex, good Eastern Cooperative
Oncology Group PS at presentation, hemoglobin levelZ10 g/dl, and single organ metastasis were signiﬁcant independent predictors of
prolonged OS. For the survival effect of metastasectomy, the median OS time of the 22 patients with metastasectomy was 53 months, which
was signiﬁcantly longer when compared with patients not undergoing metastasectomy (15 mo). After adjustment for the 4 aforementioned
prognostic factors, metastasectomy still remained signiﬁcant (hazard ratio: 0.364, P ¼ 0.0008).
Conclusions: Female sex, more favorable PS at presentation, hemoglobin level410 g/dl, and single organ metastasis were favorable
prognostic factors. In addition, metastasectomy was associated with long-term disease control.r 2016 The Authors. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Combinations of gemcitabine plus cisplatin (GC) or
methotrexate, vinblastine, doxorubicin, and cisplatin.urolonc.2016.08.016
uthors. Published by Elsevier Inc. This is an open acc
rg/licenses/by-nc-nd/4.0/).
Tel.: þ81-11-716-1161, ext: 5949; fax: þ81-11-
a@rf6.so-net.ne.jp (T. Abe).(MVAC) have become established as the standard ﬁrst-
line regimens for the treatment of metastatic urothelial
carcinoma (UC), and initial response rates of approximately
50% to 70% have been reported. However, a large
proportion of patients subsequently become refractory to
the treatment, and patients resistant to the initial treatment
represent a big challenge in daily clinical practice. In the
GC era, although the salvage strategy has not been fullyess article under the CC BY-NC-ND license
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studied, such as paclitaxel-based systemic chemotherapy
[1,2]. Furthermore, bone-modifying agents could be added
for patients with bone metastases [3], or the resection of
metastasis (metastasectomy) has been performed in very
selected patients with oligometastasis, aiming to eliminate
the disease surgically [4–9]. Clinicians have been devising
the treatments case by case, using their limited armamenta-
rium. In the present study, we aimed to clarify prognostic
factors of metatstatic UC treated by systemic chemotherapy
based on real-world clinical practice in the Japanese
population.2. Materials and methods
2.1. Patients
After institutional review board approval, we collected
the medical records of 259 patients with metastatic
UC undergoing systemic chemotherapy at Hokkaido
University Hospital and 6 afﬁliated community hospitals
between 2000 and 2013. First, we excluded the patients
undergoing fewer than 2 cycles of systemic chemotherapy
(n = 13), because, in our experience, the situation that
patients discontinued chemotherapy only after 1 cycle
strongly suggests that their original health status was not
appropriate for initiation of systemic chemotherapy, or
rapidly got worsen during the treatment. Because we aimed
to clarify prognostic factors in the treatment of systemic
chemotherapy in the Japanese population, we excluded
those patients. Furthermore excluding the patients under-
going chemotherapy for locally advanced disease or in
an adjuvant setting (n = 9), those with a histology of
pure-small-cell carcinoma (n = 4), or those with missing
data (n = 5), a total of 228 patients were included in the
present study.
2.2. Treatments
Although we did not have strict prospective treatment
guidelines across our institutions, our general treatment
strategy was as follows. Regarding ﬁrst-line chemotherapy,
in the early study period, we started the MEC regimen
(methotrexate, epirubicin, and cisplatin), which was rela-
tively common in Japan based on a prospective randomized
study whereby a similar response rate and incidence of
adverse effects when compared with those after MVAC was
observed [10]. In the later period, based on the results of a
GC study [11] and government approval in Japan in 2008,
the GC regimen was selected as ﬁrst-line chemotherapy. In
patients achieving disease control, we continued the regi-
men by replacing cisplatin with carboplatin or by prolong-
ing the interval of treatment or both. In patients refractory to
ﬁrst-line chemotherapy, we considered second-line chemo-
therapy. For metastasectomy, we generally considered it forpatients with oligometastasis, a good performance status
(PS) and good response to chemotherapy, as previously
reported [4]. In patients with impaired renal function, we
considered a dose reduction of chemotherapeutic agents.
Usually, as a general rule among our group, we considered
dose reduction according to 24-hour Ccr before each cycle.
For example, regarding cisplatin, we applied a 75% dose if
24-hour Ccr was between 45 and 60 ml/min/1.73 m2 or a
50% dose if between 30 and 45 ml/min/1.73 m2. However,
this was our general rule and the decision was up to each
physician. Recently, a carboplatin-based regimen was also
selected ﬁrst in cases o60 ml/min/1.73 m2. Our dose
reduction rules regarding other drugs were previously
reported [12]. Regarding the body surface area correction,
1.73 m2 was currently used.
2.3. Statistical methods
Overall survival (OS) was analyzed from the start of
chemotherapy until death or the last follow-up according to
the Kaplan-Meier method, using the log-rank test to assess
the signiﬁcance of differences. Regarding the patients
undergoing metastasectomy before systemic chemotherapy
(n ¼ 5), the survival time was calculated from the date of
metastasectomy until death or the last follow-up. The Cox
proportional hazards model was used to evaluate the
relationship between clinical characteristics and survival.
The characteristics analyzed were age, sex, ECOG-PS,
primary site, pathology of primary site, hemoglobin (Hb)
level, lactate dehydrogenase level, C-reactive protein level,
corrected calcium level, estimated glomerular ﬁltration rate
level, history of prior chemotherapy, resection of the
primary site, each metastatic site (lymph node, lung, liver,
bone, local recurrence, and visceral metastasis [lung, live, or
bone]), number of metastatic organs, and metastasectomy.
All calculations were performed using JMP version 12.
A Po 0.05 was considered signiﬁcant.3. Results
3.1. Characteristics of the patients
Table 1 shows a summary of the patients’ characteristics.
The median patient age was 67 years (range: 30–83).
Approximately one-quarter of the cohort was female
patients (54/228, 23.7%). The ECOG-PS was score 0 in
167 patients, score 1 in 38 patients, score 2 in 9 patients,
score 3 in 2 patients, and unknown in 12 patients. The
primary cancer origin was the bladder in 111, upper urinary
tract (UUT) in 98, both in 15, and urethra/prostate in 4.
Regarding the metastatic site, 151 patients had disease in
the lymph nodes, 86 in the lung, 46 in bone, and 20 in the
liver, and local recurrence was noted in 19 (there were
overlapping cases). Regarding the baseline renal function,
122 (122/224, 54.5%) patients were considered to be
Table 1
Patients’ characteristics.
　 n¼ 228
Age, year median 67 (range, 30-83)
Sex male / female
Male 174 (76.3%)
Female 54 (23.7%)
ECOG performance status
0 167 (73.2%)
1 38 (16.7%)
2 9 (3.9%)
3 2 (0.9%)
Unknown 12 (5.3%)
Primary site
Bladder 111 (48.7%)
Upper urinary tract 98 (43.0%)
Both 15 (6.6%)
Urethra/prostate 4 (1.8%)
Pathology of primary site
Pure urothelial carcinoma 175 (76.8%)
Others 36 (15.8%)
Cytology positive 17 (7.5%)
Baseline laboratory data
Hemoblobin, g/dL (n¼ 224) median 12.1 (range, 7.3-17.8)
Lactic dehydrogenase, IU/L (n¼ 225) median 194 (range, 105-1154)
CRP, mg/dL (n¼ 223) median 0.48 (range, 0.01-19.87)
Corrected calcium, mg/dL (n¼ 209) median 9.5 (range, 4.1-11.7)
Estimated GFR (eGFR), mL/min./
1.73 m2 (n¼ 224)
median 57.6 (range, 21.2-130.1)
eGFR (n¼ 224)
Fit (Z60 mL/min./1.73 m2) 102 (45.5.%)
Cisplatin-unﬁt (o60 mL/min./
1.73 m2 )
122 (54.5%)
Prior chemotherapy
Yes 25 (11.0%)
Neoadjuvant chemotherapy 2 (0.9%)
Adjuvant chemotherapy 9 (3.9%)
Neoadjuvantþadjuvant 1 (0.4%)
Unknown 13 (5.7%)
No 201 (88.2%)
Unknown 2 (0.9%)
Primary site at the initiation of
chemotherapy
Resected 121 (53%)
Not resected 107 (47%)
Metastatic site
Lymph node 151 (66.2%)
Lung 86 (37.7%)
Bone 46 (20.2%)
Liver 20 (8.8%)
Local recurrence 19 (8.3%)
Visceral metastasis (lung, liver, or
bone)
Yes 120 (52.6%)
No 108 (47.4%)
Resection of metastasis
Yes 22 (9.6%)
No 206 (90.4%)
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than 60 ml/min/1.73 m2). During the treatment course, 22
patients (22/228, 9.6%) underwent metastasectomy, aiming
at surgical consolidation.3.2. Summary of systemic chemotherapy
Table 2 shows a summary of ﬁrst-line and second-line
chemotherapy regimens. The GC regimen was administered
as ﬁrst-line chemotherapy to 131 patients, whereas MVAC
or its modiﬁed regimen was given to 71 patients (MEC:
n ¼ 52; methotrexate, epirubicin, nedaplatin: n ¼ 16;
MVAC: n ¼ 3). For second-line chemotherapy, the PIN
regimen (paclitaxel, ifosphamide, and nedaplatin, a cisplatin
analogue developed in Japan) was dominant (56.6%,
69/122), because our group was performing a phase II
study and the PIN regimen consequently became the most
familiar paclitaxel-based systemic chemotherapy among our
group [1]. Overall, 5 patients underwent the same regimen
used in their ﬁrst-line chemotherapy according to an initial
good response, at a median of 10 months (range: 5–28) after
the start of treatment. Of the 228 patients, 119 underwent at
least 2 different regimens during their treatment courses
(2 regimens: n ¼ 83, 3 regimens: n ¼ 35, and 4 regimens:
n ¼ 1). Overall, patients in our cohort underwent a median
of 6 cycles of chemotherapy (range: 2–28). Regarding bone-
modifying agents, they were used in 48 patients owing to
bone metastasis (n ¼ 39) or hypercalcemia (n ¼ 9).
3.3. Survival outcomes
Fig. 1 shows an OS curve for 228 patients. The median
survival time was 17 months (95% CI: 14–19). Table 3
shows the results of univariate and multivariate analyses on
pretreatment prognostic characteristics. The multivariate
model identiﬁed the 4 independent pretreatment character-
istics. Female sex, good ECOG-PS at presentation, an Hb
level of more than 10 g/dl, and single organ metastasis were
associated with prolonged OS.
3.4. Summary of metastasetomy
As described earlier, 22 patients underwent metastasec-
tomy. Table 4 shows a summary of the resection of
metastases. A large proportion of the patients had PS 0
status (86%, 19/22) and underwent metastasectomy after ﬁrst-
line chemotherapy (68%, 15/22). Pulmonary resection was
most frequently performed, followed by lymphadenectomy.
Fig. 2 shows an OS curve for the 22 patients undergoing
metastasectomy. The median survival time was 53 months
(95% CI: 25-not reached), which was signiﬁcantly longer
when compared with patients who did not undergo meta-
stasectomy (15 mo). After adjusting for the 4 aforementioned
prognostic factors, metastasectomy remained signiﬁcant
(Table 5, hazard ratio: 0.364, P ¼ 0.0008).4. Discussion
In the present study, we aimed to identify the prognostic
factors in patients with metastatic UC treated by systemic
Table 2
Summary of chemotherapy regimens
No. of patients,
n ¼ 228
First-line regimens
GC (gemcitabine, cisplatin) 131
MEC (methotrexate, epirubicin, cisplatin) 52
Methotrexate, epirubicin, nedaplatin 16
MVAC (methotrexate, vinblastine, doxorubicin,
cisplatin)
3
PIN (paclitaxel, ifosfomide, nedaplatin) 14
Gemcitabine, carboplatin 7
Gemcitabine 3
Gemcitabine, nedaplatin 1
Paclitaxel 1
n ¼ 122
Second-line regimens
PIN (paclitaxel, ifosfomide, nedaplatin) 69
Gemcitabine, carboplatin 17
GC (gemcitabine, cisplatin) 15
Gemcitabine 9
MEC (methotrexate, epirubicin, cisplatin) 4
Methotrexate, epirubicin, nedaplatin 2
Paclitaxel, carboplatin 2
Gemcitabine, docetaxel 1
Gemcitabine, nedaplatin 1
Gemcitabine, paclitaxel 1
MVAC (methotrexate, vinblastine, doxorubicin,
cisplatin)
1
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GC regimen as ﬁrst-line chemotherapy, approximately 50%
(119/228) underwent at least 2 different regimens, and
metastasectomy was performed in very selected patients.
We consider that our heterogeneous cohort reﬂected the
situation in daily clinical practice in the real-world. Overall,
the multivariate model revealed that a more favorable PS
at presentation, normal Hb level410 g/dl, single organ
metastasis, and female sex were favorable prognosticFig. 1. Overall survival curve for all patients. The median survival time
was 17 months (95% CI: 14–19). (Color version of ﬁgure is available
online.)factors. In addition, metastasectomy was associated with
long-term disease control after adjusting for other prognos-
tic factors.
Regarding the Hb level and PS at presentation, our
observations were in line with previous studies. For
example, using the data of 308 metastatic patients with
UC participating in 7 phase II cisplatin-based chemotherapy
trials, the Memorial Sloan-Kettering Cancer Center study
group identiﬁed 4 prognostic factors: PS, Hb level, albumin
level, and visceral metastasis [13]. In patients treated by
salvage systemic chemotherapy, Bellmunt et al. [14]
reported that an ECOG-PS of more than 0, a Hb level less
than 10 g/dl, and the presence of liver metastasis were
adverse prognostic factors in a multivariate model. In
metastatic site, we observed that single organ metastasis
was a signiﬁcant independent predictor of prolonged
survival, consistent with the observation by Bellmunt
et al. [14]. Nakagawa et al. [15] also identiﬁed the same
trend in 114 patients who developed disease recurrence
after radical cystectomy. Although, in the present study,
liver metastasis did not remain signiﬁcant on the multi-
variate model, we agree with the previous studies in that
liver metastasis was one of the most difﬁcult sites to treat.
Our low incidence of liver metastasis (8.8%, 20/228) might
inﬂuence the statistical results.
In the present study, we observed prolonged OS in
female patients with metastatic UC treated by systemic
chemotherapy. In stage M0 bladder cancer, several studies
previously reported the opposite tendency, whereby
women with UC showed poorer survival. For example,
Otto et al. [16], in a large German multi-institutional study
(n ¼ 2,483), observed that female patients had a greater
risk of cancer-speciﬁc mortality than male patients
(5-y cancer-speciﬁc survival, male ¼ 66%, female ¼
60%, and log-rank test, P ¼ 0.005). Kluth et al. [17], in a
large international multi-institutional study (n ¼ 8,102),
observed a similar trend (5-y cancer-speciﬁc survival, male
¼ 76%, female ¼ 72%, and hazard ratio in multivariate
model: 1.17, P ¼ 0.004). Very recently, in metastatic UC,
Haines et al. [18], in a pooled cohort derived from 8 phase
II/III trials of ﬁrst-line cisplatin-based chemotherapy (male:
n ¼ 443, female: n ¼ 100), observed that female patients
with metastatic UC showed similar survival outcomes
compared with male patients. Furthermore, after stratiﬁca-
tion by ﬁrst-line regimen, they observed signiﬁcantly longer
survival in women compared with men undergoing MVAC,
whereas there was not a signiﬁcant difference in patients
undergoing GC. At present, we cannot state that our
observation is universal or biased, and do not have a clear
explanation of the sex-dependent disparity of survival in
patients with metastatic UC. Evaluation in another large
cohort is warranted. Regarding the number of chemotherapy
cycles performed in our cohort, there was no signiﬁcant
difference between the 2 groups (male: a median of 6
cycles, female: a median of 6 cycles, and Wilcoxon test:
P ¼ 0.86, data not shown).
Table 3
Univariate and multivariate analyses of pretreatment prognostic characteristics.
　 No. of patients Median survival,
months (95% CI)
p-value Hazard ratio (95% CI) p-value
Age, year
Z67 119 16 (13-19) 0.7216
o67 109 19 (14-23)
Sex male / female
male 174 16 (13-18) 0.0003 1 0.0002
female 54 27 (17-73) 0.481 (0.313-0.717)
Performance status
Z1 49 8 (6-10) o0.0001 1 0.0004
0 167 19 (17-26) 0.483 (0.330-0.716)
Primary site
bladder only 111 20 (17-27) 0.0194 1 0.141
others 117 15 (13-17) 1.287 (0.920-1.804)
Pathology of primary site
pure urothelial carcinoma 175 18 (15-22) 0.7121
others 36 15 (9-25)
Hemoglobin
o10 g/dL 29 7 (6-11) 0.0004 1 0.0292
Z10 g/dL 195 18 (16-21) 0.567 (0.355-0.942)
LDH
Z200 100 15 (10-19) 0.2316
o200 125 19 (15-24)
CRP
Z1 77 9 (7-13) 0.0044 1 0.3996
o1 146 19 (17-24) 0.855 (0.599-1.234)
Corrected calcium
Z10 26 8 (6-19) 0.002 1 0.1153
o10 183 18 (16-22) 0.670 (0.423-1.108)
eGFR
ﬁt 102 20 (16-29) 0.1366
cisplatin-unﬁt 122 15 (13-18)
Prior chemotherapy
yes 25 19 (13-22) 0.9965
no 201 17 (14-20)
Resection of primary site
yes 121 19 (17-26) 0.0075 1 0.216
no 107 13 (11-18) 1.234 (0.884-1.723)
Lymph node metastasis
yes 151 15 (12-17) 0.0346 1 0.9744
no 77 22 (17-28) 0.994 (0.672-1.458)
Lung metastasis
yes 86 14 (10-19) 0.0584
no 142 18 (15-23)
Liver metastasis
yes 20 9 (4-18) 0.011 1 0.9185
no 208 17 (15-21) 1.032(0.580-1.925)
Bone metastasis
yes 46 16 (10-19) 0.2284
no 182 17 (14-21)
Local recurrence
yes 19 24 (6-not reached) 0.1109
no 209 17 (14-19)
Visceral metastasis (lung, liver, or bone)
yes 120 16 (11-19) 0.0622
no 108 17 (15-26)
Number of metastatic organs
two or more 85 11 (8-16) o0.0001 1 0.0168
single 143 20 (17-27) 　 0.640 (0.447-0.922) 　
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disease originating from UUT. It seemed a higher number
than that expected in the United States of America of
approximately 10% of UC based on recent studies [19,20].
According to 2014 vital statistics conducted by the Ministry
of Health, Labour and Welfare in Japan, the annual death
number in 2014 was 1967 of renal pelvic neoplasm, 1816
of ureteric neoplasm, and 7760 of bladder neoplasm
(http://www.mhlw.go.jp/toukei/index.html). Another recent
Japanese multi-institutional study, regarding the outcomes
of systemic chemotherapy for initially inoperative meta-
static or recurrent/metastatic UC after radical surgery, also
reported a high number of UC of the UUT cases (bladder:
n = 151, UUT: n = 147) [21]. Although UC of the UUT
might represent a different biology compared with bladder
cancer, the aforementioned study showed similar clinical
response rates for systemic chemotherapy between UC of
the bladder and UC of the UUT in metastatic UC [21].
At present, we cannot state the reason for the high incidence
of UC of the UUT in Japan. The high incidence of UC of
the UUT was also observed in Taiwan [22], another East
Asian country. Although chronic exposure to arsenic
contaminated water, which cause blackfoot disease (BFD),
was suspected as a possible reason for the high incidence in
Taiwan, the relationship between BFD and UC of the UUT
remains unclear, because there is also a high incidence of
these tumors in the northeast end of the island (approx-
imately 20% of UC) where BFD is not a problem [22].
Regarding the proportion of variant histologic patterns, theTable 4
Summary of metastasectomy, n ¼ 22
Age, y Median 68 (range: 54–78)
Sex
Male 13
Female 9
ECOG performance status
0 19
1 1
2 1
Unknown 1
Timing of metastasectomy
Before systemic chemotherapy 5
After ﬁrst-line chemotherapy 15
After second-line chemotherapy 2
Procedures
Pulmonary resection 11
Retroperitioneal LND 3
Distant LND 2
Resection of local recurrence 1
Resection of subcutaneous metastasis 1
Liver resection 1
Bone resection 1
Adlenalectomy 1
Colon resection 1
LND ¼ lymph node dissection.present observation of 15.8% of UC with other histological
variants was within the low range among previous reports
[23,24]. Because a recent study observed the underreported
incidence of histologic variants in community practice, a
lack of central pathology review in the present study might
be one of the reasons [25].
As described earlier, in second-line chemotherapy, the
PIN regimen was dominant (57%, 69/122) in the present
cohort, because our group was performing a phase II study
during the study periods, and that regimen became the most
familiar taxan-based regimen among our teaching hospitals
[1]. Nedaplatin is a second-generation cisplatin analogue
developed in Japan, that has shown equivalent antitumor
activity and lower nephrotoxicity and gastrointestinal tox-
icity than cisplatin, although its myelosuppressive toxicity
can be a dose-limiting factor [26,27]. In the phase II study,
nedaplatin monotherapy showed a 28% (10/35) response
rate against UC [28]. So far, several Japanese groups,
including ours, have reported the outcomes of PIN regimen
for refractory metastatic UC, and the overall response rate
was 30% to 75% and median OS time was 8.9 to 22
months. Grade 3/4 neutropenia was the most frequent
toxicity [1,29,30].
Surgical consolidation has been performed in selected
patients with metastatic UC, and their outcomes were
accumulated [31]. For example, in a German multi-
institutional study, Lehman et al. [5] showed survival
outcomes in 44 patients with distant metastases undergoing
their complete resection. The median OS from the time of
metastasectomy was 27 months. Matsuguma et al. also
reported a 5-year OS rate of 50% in 32 patients with
metastatic UC undergoing pulmonary metastasectomy with
a curative intent [9]. Our study furthermore supported the
positive role of metastasectomy in selected patients with
metastatic UC. The median survival time was 53 months
(95% CI: 25-not reached), which was signiﬁcantly longer
when compared with patients who did not undergoFig. 2. Overall survival curve for the 22 patients undergoing metastasect-
omy. The median survival time was 53 months (95% CI: 25-not reached),
which was signiﬁcantly longer than that of patients who did not undergo
metastasectomy (15 mo). (Color version of ﬁgure is available online.)
Table 5
Multivariate analysis adjusting for resection of metastasis and the four
prognostic factors identiﬁed in the present study.
　 No. of
patients
Hazard ratio
(95% CI)
p-value
Sex male / female
male 174 1 0.002
female 54 0.548 (0.360-0.809)
Performance status
Z1 49 1 o0.0001
0 167 0.454 (0.319-0.658)
Hemoglobin
o10 g/dL 29 1 0.0145
Z10 g/dL 195 0.547 (0.354-0.882)
Number of metastatic
organs
two or more 85 1 0.0014
single 143 0.595 (0.435-0.817)
Resection of metastasis
no 206 1 0.0008
yes 22 0.364 (0.171-0.680)
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resection had been most frequently performed, and, at least
in 6 patients, video-assisted thoracic surgery was conducted
(data not shown). This might reﬂect recent progress in
endoscopic surgery, including video-assisted thoracic sur-
gery, motivating patients and physicians to face the
challenge of surgical elimination, if their metastasis can
be minimum invasively resected. Recently, the feasibility
and improved postoperative convalescence of laparoscopic
liver resection of colorectal metastases has been reported
[32,33]. Although solitary liver metastasis is not a frequent
situation in patients with metastatic UC and, in the present
study, there was only single patient treated by open
hepatectomy, laparoscopic surgery could become an alter-
native to open hepatectomy. However, owing to the low
number of cases in studies so far, including ours, a
deﬁnitive conclusion regarding the role of metastasectomy
cannot be drawn. We still require future studies. At present,
surgical elimination should be considered very carefully in
well-selected patients.
In Europe, vinﬂunine, a novel agent of the vinca alkaloid
family, is available in clinical practice for patients with
platinum-resistant metastatic UC, based on a pivotal phase
III randomized study, whereby patients receiving vinﬂunine
showed longer OS compared with a control group.
Although the survival difference in the intention-to-treat
population (n = 370) was not statistically signiﬁcant (6.9 vs.
4.6 mo, respectively, P = 0.287), a signiﬁcant difference
(6.9 vs. 4.3 mo, respectively, P = 0.04) was observed after
excluding 13 noneligible patients with at least single major
protocol violation at baseline [34]. Unfortunately, it has yet
to be approved in Japan, so we cannot comment on
the potential role of this drug. In May 2016, the U.S. Food
and Drug Administration approved atezolizumab, PD-L1inhibitor, for the treatment of patients with locally
advanced/metastatic UC whose disease had worsened dur-
ing or after platinum-based chemotherapy. In the near
future, immune checkpoint inhibitors, including atezolizu-
mab, may make marked progress to improve the treatment
outcome of patients with metastatic UC [35,36]. Never-
theless, we expect the prognostic characteristics previously
identiﬁed, including those we reported, to remain important,
and surgical elimination would be performed in well-
selected patients.
We recognize that our study is limited by its retrospec-
tive nature and small number of patients. Because there was
a small number of patients with4PS1, it might be hard to
draw a deﬁnitive conclusion regarding the effect of PS,
although our ﬁndings were consistent with previous studies.
The regimen used in the current population was so
heterogeneous that we could not assess which sequential
pattern was superior to others. Host immune reaction
toward the carcinoma might also be a prognostic factor,
although we could not examine this factor in the present
analysis. Future study is needed to clarify the survival effect
of immunological response, especially in surviving cases.
Of particular note, we did not have strict prospective criteria
for metastasectomy. Nevertheless, we consider that several
important ﬁndings were generated by the present study.5. Conclusions
Female sex, more favorable PS at presentation, normal
Hb level Z10 g/dl, and single organ metastasis were
favorable prognostic factors. In addition, metastasectomy
was associated with long-term disease control.References
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